Free

Trans-NIH Workshop on Sickle Cell Disease Pain

Actions and Detail Panel

Free

Event Information

Share this event

Date and time

Location

Location

Online event

Event description
Approaches to Effective Therapeutic Management of Pain for People with Sickle Cell Disease (SCD)

About this event

This trans–National Institutes of Health (NIH) workshop will focus on sickle cell disease pain. Researchers will explore critical gaps and research challenges as well as brainstorm potential solutions for this grossly understudied pain condition in a highly underserved population. This fits into the NIH mission of seeking fundamental knowledge to enhance health. The meeting planning is being led by the National Center for Complementary and Integrative Health and the National Heart, Lung, and Blood Institute.

The agenda and registration information will be shared widely in June.

Dates:

Wednesday, July 21; 11:30 a.m.–5:30 p.m.

Thursday, July 22; 11:30 a.m.–5:30 p.m.

Co-Leads: NCCIH & NHLBI

Collaboration Partners: NICHD, NIDA, NIMHD, NINDS, NINR

Draft Agenda

July 21, 2021

11:30 a.m.–12:00 p.m. | Welcome and opening remarks

  • 11:30–11:45 a.m. To be determined [TBD]
  • 11:45 a.m.–12:00 p.m. | [TBD]

12:00–12:30 p.m. | Keynote—Wally Smith, M.D., Virginia Commonwealth University. Inspirational keynote on the state of science of pain in SCD

12:30–12:35 p.m. | Questions and answers from NIH VideoCast audience

Session 1: Understanding Acute and Chronic SCD Pain: What Do We Know?

12:35–1:55 p.m. | Expert group 1—biology of SCD pain

  • 12:35–12:50 p.m. | Robert Hebbel, M.D., University of Minnesota. Biology of acute SCD pain crisis
  • 12:50–1:05 p.m. | Kalpna Gupta, Ph.D., University of Minnesota. Biology of chronic SCD pain
  • 1:05–1:15 p.m. | Panel commentary (approximately 2 minutes per panelist)
  • Allison King, M.D., Ph.D., Washington University in St. Louis. Cognitive aspects of acute and chronic SCD pain
  • Richard Harris, Ph.D., University of Michigan. Neuroimaging of chronic SCD pain
  • [TBD] Potential connections between myofascial and skeletal tissues and acute and chronic SCD pain
  • Anjulika Chawla, M.D., Brown University. Gaps in knowledge in the musculoskeletal aspects of SCD pain
  • Jerlym Porter, Ph.D., M.P.H., St. Jude Children’s Research Hospital. Predictors of pediatric acute and chronic SCD pain
  • 1:15–1:45 p.m. | Panel discussion. Moderators: Wen Chen, Ph.D., National Center for Complementary and Integrative Health (NCCIH); William Tonkins, Ph.D., National Heart, Lung, and Blood Institute (NHLBI)
  • What are the major gaps in our current knowledge of the biology underlying acute and chronic SCD pain?
  • What tools, methodology, technology, animal models, or additional resources are needed to fill these knowledge gaps?
  • 1:45–1:55 p.m. | Questions and answers from NIH VideoCast audience

1:55–2:05 p.m. | Break

2:05–3:10 p.m. | Expert group 2—psychosocial and environmental factors impacting SCD pain

  • 2:05–2:15 p.m. | Cecelia Valrie, Ph.D., Virginia Commonwealth University. The impact of psychological and sleep influences on acute or chronic SCD pain
  • 2:15–2:25 p.m. | Shawn Bediako, Ph.D., NHLBI. Social and ecological contexts of acute and chronic SCD pain
  • 2:25–2:35 p.m. | Panel commentary (approximately 3 minutes per panelist)
  • Patricia Kavanagh, M.D., Boston University. Impact of bias on acute and chronic SCD pain experience and behaviors
  • Soumitri Sil, Ph.D., Emory University. Pediatric acute and chronic SCD pain: psychosocial outcomes
  • Lori Crosby, Psy.D., Cincinnati Children’s Hospital Medical Center. Socioeconomic effects on acute and chronic SCD pain
  • 2:35–3:05 p.m. | Panel discussion. Moderators: Shawn Bediako, Ph.D., NHLBI; Nishadi Rajapakse, Ph.D., National Institute on Minority Health and Health Disparities
  • What are the major gaps in current knowledge regarding the psychosocial and environmental factors influencing acute and chronic SCD pain?
  • What tools, methodology, technology, policies, guidelines, or additional resources are needed to fill these knowledge gaps?
  • 3:05–3:10 p.m. | Questions and answers from NIH VideoCast audience

3:10–4:10 p.m. | Expert group 3—genetics/microbiome factors impacting SCD pain

  • 3:10–3:20 p.m. | Amanda Brandow, D.O., Children’s Wisconsin. The role of the microbiome in the development of acute and chronic SCD pain
  • 3:20–3:30 p.m. | Zaijie (Jim) Wang, Ph.D., University of Illinois, Chicago. Genetic factors influencing acute and chronic SCD pain
  • 3:30–3:35 p.m. | Panel commentary
  • Seena Ajit, Ph.D., Drexel University. Molecular mechanisms underlying acute and chronic pain, with emphasis on epigenetics
  • 3:35–4:05 p.m. | Panel discussion. Moderators: Inna Belfer, M.D., Ph.D., NCCIH; Karen Lee, M.D., M.P.H., Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • What are the major gaps in current knowledge related to the genetic, epigenetic, and microbiome factors influencing acute and chronic SCD pain?
  • What tools, methodology, technology, animal models, or additional resources are needed to fill these knowledge gaps?
  • 4:05-4:10 p.m. | Questions and answers from NIH VideoCast audience

4:10–4:20 p.m. | Break

4:20–4:30 p.m. | Patient perspective, Lakiea Bailey, Ph.D., Living with SCD: my pain story

4:30–5:30 p.m. | Roundtable discussion 1—challenges and opportunities for understanding acute and chronic SCD pain

Lead discussants

  • Daniel Clauw, M.D., University of Michigan. Summary of responses from invited participants to the question about knowledge gaps and research opportunities for research on acute and chronic SCD pain
  • Theodore Price, Ph.D., University of Texas at Dallas. Summary of responses from invited participants to the question about the tools, methodology, technology, policies, guidelines, animal models, and additional resources needed to address acute and chronic SCD pain
  • Roger Fillingim, Ph.D., University of Florida. Summary of responses from invited participants to the question about aspects of research on other pain conditions that could be applied to research on acute and chronic SCD pain

5:30 p.m. | Adjourn

July 22, 2021

11.30–11:40 a.m. | Welcome and opening remarks [TBD]

11:40 a.m.–12:10 p.m. | Keynote—Cheryl Stucky, Ph.D., Medical College of Wisconsin. Sickle cell pain chasm 2021: knowns, unknowns, and bridges forward

Session 2: Challenges and Opportunities for Optimizing SCD Pain Management

12:10–1:20 p.m. | Expert group 4—measuring pain and sequelae in patients for clinical trials

  • 12:10–12:20 p.m. | Thomas Coates, M.D., University of Southern California. Acute and experimental SCD pain
  • 12:20–12:30 p.m. | Diana Wilkie, Ph.D., R.N., University of Florida. Clinical presentation of chronic SCD pain: descriptors and phenotypes
  • 12:30–12:40 p.m. | Panel commentary (approximately 2 minutes per panelist)
  • William Zempsky, M.D., M.P.H., University of Connecticut. Systematic approaches to pediatric acute and chronic SCD pain, location of pain, and PhenX measures
  • Carlton Dampier, M.D., Emory University. Quality of life in children with chronic SCD pain, epidemiology
  • Nitya Bakshi, M.D., Emory University. Modifying the manifestation of chronic pain and opioid use in SCD, phenotyping and pain variability
  • Laura De Castro, M.D., University of Pittsburgh. Patterns and correlates of daily chronic SCD pain, lessons from contemporary drug trials in acute and chronic pain measurement
  • 12:40–1:10 p.m. | Panel discussion. Moderators: Will Aklin, Ph.D., National Institute on Drug Abuse; Smriti Iyengar, Ph.D., National Institute of Neurological Disorders and Stroke
  • Other than pain severity, what outcomes should be measured in clinical trials studying SCD pain management interventions?
  • What functional outcomes, co-occurring conditions, or social determinants of health measures are important to patients or are critical confounders that should be considered in analytic plans?
  • 1:10–1:20 p.m. | Questions and answers from NIH VideoCast audience

1:20–1:30 p.m. | Break

1:30–2.40 p.m. | Expert group 5—current or promising treatments for acute and chronic SCD pain

  • 1:30–1:40 p.m. | C. Patrick Carroll, M.D., Johns Hopkins University. Treatment strategies to manage acute and chronic SCD pain in patients experiencing crisis
  • 1:40–1:50 p.m. | Judith Schlaeger, Ph.D., University of Illinois, Chicago. Managing chronic SCD pain with nonpharmacologic approaches
  • 1:50–2:05 p.m. | Panel commentary (approximately 2 minutes per panelist)
  • Michael V. Vitiello, Ph.D., University of Washington. The potential of cognitive behavior therapy for insomnia to manage chronic pain and comorbid insomnia
  • Ardith Doorenbos, Ph.D., R.N., University of Illinois, Chicago. Patient engagement and implementation of complementary interventions in clinical settings
  • Bin He, Ph.D., Carnegie Mellon University. Ultrasound neuromodulation for acute and chronic SCD pain management
  • Lynnette Kaid, SorsaMED. Potential therapeutic proteins infused with cannabinoids for chronic SCD pain management
  • Alexis Leonard, M.D., NHLBI. Residual chronic pain following gene therapy for SCD
  • Deepika Darbari, M.D., Children’s National Hospital. Post-transplantation chronic pain persistence
  • 2:05–2:30 p.m. | Panel discussion. Moderators: Jeri Miller, Ph.D., National Institute of Nursing Research; Della White, Ph.D., NCCIH
  • What effective treatments or models relevant to SCD pain management could be adopted, adapted, integrated, or scaled up in various health care systems?
  • What promising multidisciplinary and multilevel interventions or multicomponent delivery models are ready for multisite efficacy or effectiveness trials for SCD pain management and related function
  • 2:30–2:40 p.m. | Questions and answers from NIH VideoCast audience

2:40–3:45 p.m. | Expert group 6—overcoming challenges of evidence-based pain management: patient engagement, stigma, bias, and access to quality care

  • 2:40–2:50 p.m. | Patricia Kavanagh, M.D., Boston University. Addressing implementation and access to quality challenges in SCD pain care
  • 2:50–3:00 p.m. | Coretta Jenerette, Ph.D., R.N., University of South Carolina. Addressing stigma and bias challenges in SCD pain care
  • 3:00–3:05 p.m. | Panel commentary (approximately 2 minutes per panelist)
  • Roger Fillingim, Ph.D., University of Florida. Addressing disparities and other potential challenges in SCD pain management
  • Shan-Estelle Brown, Ph.D., Rollins College. Using cultural competence/sensitivity approaches and minimizing structural barriers to improve SCD pain management
  • 3:05–3:35 p.m. | Panel discussion. Moderators: Susan Shero, R.N., M.S., NHLBI; Wendy Weber, N.D., Ph.D., M.P.H., NCCIH
  • What successful strategies from other fields could be evaluated in trials to address stigma, enhance access to quality care, reduce bias, and overcome structural barriers in acute and chronic SCD pain management?
  • 3:35–3:45 p.m. | Questions and answers from NIH VideoCast audience

3:45–3:55 p.m. | Break

3:55–4:05 p.m. | Patient perspective, Shauna Whisenton. Living with SCD: personal experience with acute and chronic pain management after SCD cure

4:05–5:25 p.m. | Roundtable discussion 2—building a future in which SCD pain management can be optimized

Lead discussants

  • Sophie Lanzkron, M.D., M.H.S., Johns Hopkins University. Summary of responses from invited participants to the questions about (1) multidisciplinary and multilevel interventions or multicomponent delivery models that are ready for multisite efficacy or effectiveness trials for acute and chronic pain management, and (2) important functional measures to be considered for such clinical trials
  • Wally Smith, M.D., Virginia Commonwealth University. Summary of responses from invited participants to the question about the barriers to and effective treatments and models for acute and chronic SCD pain management that could be adopted, adapted, integrated, and scaled up in various health care systems
  • Cheryl Stucky, Ph.D., Medical College of Wisconsin. Summary of responses from invited participants to the question about successful strategies from other fields that could be evaluated in trials to address stigma, enhance access to quality care, reduce bias, and overcome structural barriers in acute and chronic SCD pain management

5:25–5:30 p.m. | Closing remarks [TBD]

5:30 p.m. | Adjourn

OMB#: 0925-0740

Expiration Date: 07/31/2022

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Share with friends

Date and time

Location

Online event

{ _('Organizer Image')}

Organizer National Center for Complementary and Integrative Health

Organizer of Trans-NIH Workshop on Sickle Cell Disease Pain

Save This Event

Event Saved